ArticleMedicine2025
Analyzing the clinical characteristics of the SCAMP5 gene in gliomas and establishing a predictive model.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are frequently occurring tumors in the nervous system. The secretory carrier membrane protein 5 (SCAMP5) plays a distinct role in the cytosolic function of mammalian cells and is associated with different neurological disorders. However, how SCAMP5 is expressed and its prognostic value in gliomas is unclear. The datasets were downloaded from the Chinese Glioma Genome Atlas website (http://www.cgga.org.cn/). We conducted a Cox survival analysis to establish a correlation between SCAMP5 gene expression and the general survival rate of patients with glioma. We performed Gene Ontology analysis to determine the biological functions of the SCAMP5 gene. Finally, we constructed a prediction model using primary relapse state type, age, grade, isocitrate dehydrogenase mutation status, 1p/19q co-deletion status, and the SCAMP5 gene expression value. Using this model, we can forecast the survival rates of patients for 1, 2, 3, 5, and 10 years. SCAMP5 was enriched in low-grade gliomas and isocitrate dehydrogenase mutant gliomas, 1p19q-deficient gliomas. SCAPM5 is an independent prognostic factor for the overall survival of glioma patients. Predictive models developed by SCAMP5 were able to predict well the long-term survival of patients. The evidence suggests that the SCAMP5 gene plays a significant function in glioma patients. There is a clear correlation between the expression of the SCAMP5 gene and the overall survival of glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.